REPLIGEN CORP Operating Expenses
REPLIGEN CORP (RGEN) reported Operating Expenses of $91.23 million for the 3-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2021-02-24
- REPLIGEN CORP operating expenses for the quarter ending 2020-12-31 was $91.23M, a 43.49% increase year-over-year.
- REPLIGEN CORP operating expenses for the quarter ending 2020-09-30 was $73.10M, a 18.90% increase year-over-year.
- REPLIGEN CORP operating expenses for the quarter ending 2020-06-30 was $67.92M, a 13.90% increase year-over-year.
- REPLIGEN CORP operating expenses for the quarter ending 2020-03-31 was $64.18M, a 29.76% increase year-over-year.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-12-31 | $91.23M 10-K · filed 2021-02-24 | $164.33M derived: sum of 2 quarters · filed 2021-02-24 | $232.25M derived: sum of 3 quarters · filed 2021-02-24 | $296.44M derived: sum of 4 quarters · filed 2021-02-24 |
| 2020-09-30 | $73.10M 10-K · filed 2021-02-24 | $141.02M derived: sum of 2 quarters · filed 2021-02-24 | $205.21M derived: sum of 3 quarters · filed 2021-02-24 | $268.79M derived: sum of 4 quarters · filed 2021-02-24 |
| 2020-06-30 | $67.92M 10-K · filed 2021-02-24 | $132.11M derived: sum of 2 quarters · filed 2021-02-24 | $195.69M derived: sum of 3 quarters · filed 2021-02-24 | $257.17M derived: sum of 4 quarters · filed 2021-02-24 |
| 2020-03-31 | $64.18M 10-K · filed 2021-02-24 | $127.76M derived: sum of 2 quarters · filed 2021-02-24 | $189.25M derived: sum of 3 quarters · filed 2021-02-24 | $248.88M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-12-31 | $63.58M 10-K · filed 2021-02-24 | $125.06M derived: sum of 2 quarters · filed 2021-02-24 | $184.70M derived: sum of 3 quarters · filed 2021-02-24 | $234.16M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-09-30 | $61.48M 10-K · filed 2021-02-24 | $121.12M derived: sum of 2 quarters · filed 2021-02-24 | $170.58M derived: sum of 3 quarters · filed 2021-02-24 | $214.67M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $59.64M 10-K · filed 2021-02-24 | $109.10M derived: sum of 2 quarters · filed 2021-02-24 | $153.19M derived: sum of 3 quarters · filed 2021-02-24 | $194.83M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $49.46M 10-K · filed 2021-02-24 | $93.55M derived: sum of 2 quarters · filed 2021-02-24 | $135.19M derived: sum of 3 quarters · filed 2021-02-24 | $178.65M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $44.09M 10-K · filed 2020-02-26 | $85.73M derived: sum of 2 quarters · filed 2020-02-26 | $129.19M derived: sum of 3 quarters · filed 2020-02-26 | $168.04M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-09-30 | $41.64M 10-K · filed 2020-02-26 | $85.10M derived: sum of 2 quarters · filed 2020-02-26 | $123.95M derived: sum of 3 quarters · filed 2020-02-26 | $162.30M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $43.46M 10-K · filed 2020-02-26 | $82.31M derived: sum of 2 quarters · filed 2020-02-26 | $120.66M derived: sum of 3 quarters · filed 2020-02-26 | $157.65M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $38.85M 10-K · filed 2020-02-26 | $77.20M derived: sum of 2 quarters · filed 2020-02-26 | $114.19M derived: sum of 3 quarters · filed 2020-02-26 | $141.17M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $38.35M 10-K · filed 2019-03-01 | $75.33M derived: sum of 2 quarters · filed 2019-03-01 | $102.32M derived: sum of 3 quarters · filed 2019-03-01 | $127.23M derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-09-30 | $36.99M 10-K · filed 2019-03-01 | $63.97M derived: sum of 2 quarters · filed 2019-03-01 | $88.88M derived: sum of 3 quarters · filed 2019-03-01 | |
| 2017-06-30 | $26.98M 10-K · filed 2019-03-01 | $51.90M derived: sum of 2 quarters · filed 2019-03-01 | ||
| 2017-03-31 | $24.91M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |